Skip to main content
Clinician wearing a facemask administering a vaccination to a male patient

Global HIV Vaccine Enterprise

AIM: To share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine

Established in 2003, the Global HIV Vaccine Enterprise became a programme of the IAS in 2018. It works to engage stakeholders and funders to accelerate HIV vaccine development and prepare the field for the future discovery of a safe, effective and globally accessible HIV vaccine.

It does so by: 

  • Strengthening the HIV vaccine pipeline by encouraging diverse approaches in HIV vaccine research and advancing the HIV vaccine portfolio
  • Expanding and diversifying engagement and resources by fostering interest in HIV vaccine R&D and broadening research talent within the HIV vaccine field
  • Mobilizing knowledge to accelerate product development by driving opportunities to address unanswered scientific questions and leveraging synergies with other infectious disease research

[email protected]

With support from:

This project was sponsored by the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Aids (DAIDS) and administered through a grant by CRDF Global.